Comparison of the effects of a 50% exchange-transfusion with albumin, hetastarch, and modified hemoglobin solutions

Shock

Volumn 17, Issue 1, 2002, Pages 61-69

  Lieberthal, Wilfred ^a,g   Fuhro, Robert ^a   Alam, Hasan ^b   Rhee, Peter ^b   Szebeni, Janos ^c   Hechtman, Herbert B ^d   Favuzza, Joanne ^d   Veech, Richard L ^e   Valeri, C Robert ^f  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^f BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^g BOSTON UNIVERSITY   (United States)

Author keywords

Colloid; Hematocrit; Hypotension; Resuscitation; Vascular resistance

Indexed keywords

BLOOD SUBSTITUTE; COMPLEMENT; HEMOGLOBIN; HETASTARCH; SERUM ALBUMIN; SOMATOMEDIN C; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; ARTICLE; BLOOD TRANSFUSION; BODY WEIGHT; COMPARATIVE STUDY; DRUG EFFECT; GLOMERULUS FILTRATION RATE; HEMATOCRIT; HEMODYNAMICS; HUMAN; KIDNEY; KIDNEY CIRCULATION; METABOLISM; METHODOLOGY; PHYSIOLOGY; RAT; SKELETAL MUSCLE; SOLUTION AND SOLUBILITY; VASCULARIZATION;

ANIMALS; BLOOD SUBSTITUTES; BLOOD TRANSFUSION; BODY WEIGHT; COMPLEMENT SYSTEM PROTEINS; GLOMERULAR FILTRATION RATE; HEMATOCRIT; HEMODYNAMIC PROCESSES; HEMOGLOBINS; HETASTARCH; HUMANS; INSULIN-LIKE GROWTH FACTOR I; KIDNEY; MUSCLE, SKELETAL; RATS; RENAL CIRCULATION; SERUM ALBUMIN; SOLUTIONS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036356603     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/00024382-200201000-00011     Document Type: Article

References (39)

1. Ernest D, Belzberg AS, Dodek PM: Distribution of normal saline and 5% albumin infusions in septic patients. Crit Care Med 27:46-50, 1999.
2. Greenough A: Use and misuse of albumin infusions in neonatal care. Eur J Pediatr 157:699-702, 1998.
3. Nichani S: Albumin: saint or sinner? Arch Dis Child 81:189, 1999.
4. Roberts JS, Bratton SL: Colloid volume expanders. Problems, pitfalls and possibilities. Drugs 55:621-630, 1998.
5. Skillman JJ: Albumin - does the bell toll for thee? Transfusion 39:120-122, 1999.
6. Waiker SS, Chertow GM: Crystalloids versus colloids for resuscitation in shock. Curr Opinion Nephrol Hypertens 9:501, 2000.
7. Choi PT, Yip G, Quinonez LG, Cook DJ: Crystalloids vs. colloids in fluid resuscitation: a systematic review. Crit Care Med 27:200-210, 1999.
8. Ferguson ND, Stewart TE, Etchells EE: Human albumin administration in critically ill patients. Intensive Care Med 278:323-325, 1999.
9. Schierhout G, Roberts I: Fluid resuscitation with colloid or crystalloid solutions in critically ill patients: a systematic review of randomized trials. BMJ 316: 961-964, 1998.
10. Winslow RM: New transfusion strategies: red cell substitutes. Annu Rev Med 50:337-353, 1999.
11. Lieberthal W, Fuhro R, Freedman JE, Toolan G, Loscalzo J, Valeri CR: O-raffinose crosslinking markedly reduces the systemic and renal vasoconstrictor effects of unmodified human hemoglobin. J Pharm Exp Ther 288:1278-1287, 1999.
12. Lieberthal W, Vogel W, Apstein C, Valeri C: Studies of the mechanism of the vasoconstrictor activity of stroma-free hemoglobin in the isolated perfused rat kidney and rabbit heart. In: Brewer G (ed): The Red Cell: Seventh Ann Arbor Conference. New York: Liss, 1989, pp 407-422.
13. Lieberthal W, Wolf EF, Merrill EW, Levinsky NG, Valeri CR: Hemodynamic effects of different preparations of stroma free hemolysates in the isolated perfused rat kidney. Life Sci 41:2525-2533, 1987.
14. Fratantoni J: Points to consider in the efficay evaluation of hemoglobin-and perfluorocarbon-based oxygen carriers. Transfusion 34:712-713, 1994.
15. Kasper SM, Walter M, Grüne F, Bischoff A, Erasmi H, Buzello W: Effects of a hemoglobin-based oxygen carrier (HBOC-201) on hemodynamics and oxygen transport in patients undergoing preoperative hemodilution for elective abdominal aortic surgery. Cardiovasc Anesthesia 83:921-927, 1996.
16. Lee IR, Neya K, Svizzero TA, Vlahakes GJ: Limitations of the efficacy of hemoglobin-based oxygen-carrying solutions. J Appl Physiol 79:236-242, 1995.
17. Reah G, Bodenham AR, Mallick A, Daily EK, Przybelski RJ: Initial evaluation of diaspirin cross-linked hemoglobin (DCLHb) as a vasopressor in critically ill patients. Crit Care Med 25:1480-1488, 1997.
18. ™, an O-raffinose crosslinked hemoglobin-based oxygen carrier. In: Chang TMS (ed): Blood Substitutes; Principles, Methods, Products and Clinical Trials. New York: Kargee Landes, 1998, pp 62-84.
19. Winslow RM, Chapman KW: Pilot scale preparation of hemoglobin solutions. In: Winslow RM, Vandegriff KD, Everse J (eds): Methods in Enzymology. Hemoglobins: Biochemical and Analytical Methods. Orlando, FL: Academic, 1994, pp 3-16.
20. Vogel W, Dennis R, Cassidy G, Apstein C, Valeri C: Coronary constrictor effect of stroma-free hemoglobin solutions. Am J Physiol 251:H413-H420, 1986.
21. Asakura T, Reilly M: Methods for the measurement of oxygen equilibration curves of red cell suspensions and hemoglobin solutions. Advances in the Biosciences. In: Nicolau EC. Oxygen Transport in Red Blood Cells. New York: Pergamon, 1986, pp 57-75.
22. Lieberthal W, Thompson A, Valeri C: Effects of nitric oxide inhibition on systemic and renal hemodynamics in the hemorrhaged rat. Kidney Blood Press Res 19:340-346, 1996.
23. Thompson A, McGarry AE, Valeri CR, Lieberthal W: Stroma-free hemoglobin increases blood pressure and GFR in the hypotensive rat: role of nitric oxide. J Appl Physiol 77:2348-2354, 1994.
24. Thompson A, Valeri C, Lieberthal W: Endothelin receptor A blockade alters hemodynamic response to nitric oxide inhibition in the rat. Am J Physiol 269:H743-H748, 1995.
25. Thompson A, Valeri C, Lieberthal W: Nitric oxide inhibition reversed renal failure induced by hemorrhagic hypotension. J Am Soc Nephrol 4:570, 1993.
26. Levinsky N, Lieberthal W: Clearance Techniques. New York: Plenum Press, 1986. pp 227-247.
27. Szebeni J, Wassef NM, Spielberg H, Rudolph AS, Alving CR: Complement activation in rats by liposomes and liposome-encapsulated hemoglobin: evidence for anti-lipid antibodies and alternative pathway activation. Biochem Biophys Res Commun 205:255-263, 1994.
28. Baxter RC, Martin JL, Beniac VA: High molecular weight insulin-like growth factor binding protein complex. Purification and properties of the acid-labile subunit from human serum. J Biol Chem 264:11843-11848, 1989.
29. Doss DN, Estafanous FG, Ferrario CM, Brum JM, Murray PA: Mechanism of systemic vasodilation during normovolemic hemodilution. Anesth Analg 81: 30-34, 1995.
30. Anand I, Chandrashekhar Y, Wander G, Chawla L: Endothelium-derived relaxing factor is important in mediating the high output state in chronic severe anemia. J Am Coll Cardiol 25:1402-1407, 1995.
31. Lamy ML, Daily EK, Brichant JF, Larbuisson RP, Demeyere RH, Vandermeersch EA, Lehot JJ, Parsloe MR, Berridge JC, Sinclair CJ, Baron JF, Przybelski RJ: Randomized trial of diaspirin cross-linked hemoglobin solution as an alternative to blood transfusion after cardiac surgery. The DCLHb Cardiac Surgery Trial Collaborative Group. Anesthesiology 92:646-656, 2000.
32. Saxena R, Wijnhoud AD, Carton H, Hacke W, Kaste M, Przybelski RJ, Stern KN, Koudstaal PJ: Controlled safety study of a hemoglobin-based oxygen carrier, DCLHb, in acute ischemic stroke. Stroke 30:993-996, 1999.
33. Sloan EP, Koenigsberg M, Gens D, Cipolle M, Runge J, Mallory MN, Rodman G Jr: Diaspirin cross-linked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock: a randomized controlled efficacy trial. JAMA 282:1857-1864, 1999.
34. Bengtsson A: Cascade system activation in shock. Acta Anaesthesiol Scand Suppl 98:7-10, 1993.
35. Watkins J, Wild G, Appleyard TN, Hardy G: Complement activation by polystarch and gelatine volume expanders. Lancet 335:233, 1990.
36. Ling PR, Schwartz JH, Bistrian BR: Mechanisms of host wasting induced by administration of cytokines in rats. Am J Physiol 272:E333-E339, 1997.
37. Frost RA, Lang CH: Differential effects of Insulin-like growth factor 1 (IGF-1) and IGF-binding protein-1 on protein metabolism in human skeletal muscle cells. Endocrinology 140:3962-3970, 1999.
38. Ding H, Kopple JD, Hirschberg R: Recombinant human insulin-like growth factor-1 accelerates recovery and reduces catabolism in rats with ischemic acute renal failure. J Clin Invest 91:2281-2287, 1993.
39. Mynarcik DC, Frost RA, Lang CH, DeCristofaro K, McNurlan MA, Garlick PJ, Steigbigel RT, Fuhrer J, Ahnn S, Gelato MC: Insulin-like growth factor system in patients with HIV infection: effect of exogenous growth hormone administration. J Acquir Immune Defic Syndr 22:49-55, 1999.